medigraphic.com
ISSN 1527-3172 (Electronic)

2007, Number 1

<< Back Next >>

MEDICC Review 2007; 9 (1)

Cuban meningococcal BC vaccine: Experiences & contributions from 20 years of application

Sotolongo PF, Campa HC, Casanueva GV, Fajardo DEM, Cuevas VIE, González GN

Language: English
References: 37
Page: 16-22
PDF size: 242.78 Kb.


ABSTRACT

This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC®) obtained by the Finlay Institute in Havana, Cuba. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningococcal disease caused by serogroup B meningococcus; it is also effective against serogroup C. VA-MENGOC-BC® has shown satisfactory results, with no serious adverse events, after application of approximately 55 million doses in some 15 countries. Also included is background information on meningococcal disease, as well as the main characteristics of VA-MENGOC-BC®, the strategy used for controlling meningococcal disease and its prevention in Cuba, and a summary of the main scientific results obtained in basic research, development, clinical evaluation, and post-marketing results (safety, efficacy-effectiveness, post-vaccination adverse events, etc.) in Cuba and elsewhere.


REFERENCES

  1. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692-4700.

  2. WHO. Weekly epidemiological record, 77th year. 2002;No. 40:329–40.

  3. Valcárcel M, Rodríguez R, Terry H. La enfermedad meningocócica en Cuba: Cronología de una Epidemia. La Habana: ECIMED; 1991.

  4. Cuevas I, Casanueva V, Galindo MA, Armesto M, Domínguez F, Mesa I, Quintero D. Exploración de eventos adversos a VA-MENGOC-BC en tres municipios de Ciudad de La Habana. VacciMonitor. 1998;Año 8, No. 7:1-7.

  5. Vacuna Antimeningocócica BC, VA-MENGOC -BC®. Certificado de Inscripción No. 1133. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). La Habana, Cuba; 1987.

  6. Campa C, Sierra VG, Gutiérrez MM, Bisset G, García L, Puentes G, Sampedro MC, Sotolongo F, Xochitl LeRiverend E, Galguera M. Método para la obtención de una vacuna de amplio espectro protector contra Neisseria meninigitidis del serogrupo B y la vacuna resultante. Patente Cubana CU 21888 A1;1989.

  7. Campa C, Sierra VG, Gutiérrez MM, Bisset G, García L, Puentes G, Sampedro MC, Sotolongo F, Xochitl LeRiverend E, Galguera M. Method for obtaining a vaccine with wide protective range against group B Neisseria meningitidis, the resulting vaccine, gammaglobulin and transfer factor. European Patent EP 0301992; 1995.

  8. Huergo CC, Sierra VG, Gutierrez MM, Bisset G, García L, Puentes G, Sampedro MC, Sotolongo F, Xochitl LeRiverend E, Galguera M. Method for obtaining a vaccine with wide protective range against group B Neisseria meningitidis, the resulting vaccine, gammaglobulin and transfer factor. US Patent No. 5,597,572; 1997.

  9. Fundaçâo Nacional de Saúde. Ministerio da Saúde. Brasil. Manual de Vigilância Epidemiológica dos Eventos Adversos Pós- Vacinaçâo; 1998.

  10. Debbag R, Stambulian D. Evaluación de las reacciones adversas asociadas con la vacuna antimeningocócica BC. Informe preliminar sobre 8,117 vacunados. Rev Hosp Niños Buenos Aires. 1994;36:158-9.

  11. Goyectche R, Pérez A, Morena G, Giacheto G, Pírez MC, Rubio I, Montano A, Ferrari A. Efectos adversos asociados a la vacuna antimeningocócica VA-MENGOC-BC®. Rev Med Uruguay. 2004;20:102-5.

  12. Sierra VG, Campa C, Valcárcel M, García JL, Izquierdo L, Sotolongo F, Casanueva V, Rico O, Rodríguez R, Terry H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals. 1991;14:195-210.

  13. Rico O, Almeyda L. Impacto de la vacunación con VA-MENGOC-BC en los niños menores de seis años en algunas provincias de Cuba. Rev Soc Argentina Pediatr Filial Córdoba. 1994;3(3): 65-8.

  14. Almeyda González L, Rico Cordeiro O. Información general sobre la enfermedad meningocócica en Cuba: vacuna para su prevención y alcance. Rev Hosp Niños Buenos Aires. 1994;36:234-41.

  15. Rodríguez AP, Dickinson F, Baly A, Martínez R. The epidemiologic impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94:433-40.

  16. de Moraes JC, Perkins BA, Camargo MCC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VI, Vasconcelos HG. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-8.

  17. Comissâo Mista Brasil-Cuba. Relatório sobre a avaliaçâo da eficácia da vacina antimeningocócica BC de origem cubana. Informe Epidemiológico do SUS. 1994 Abril/Mai/Jun.

  18. Costa EA, Amaral C, Juarez E. Eficacia da vacina antimeningocócica (VA-MENGOC-BC®) nas condiçoes de uso no Brasil, no periodo 1989/90. CENEPI, Informe Epidemiológico do SUS. 1994 Abr/Mai/Jun.

  19. Noroña CP, Baran M, de Araujo CC, Ocampo AT, Torres G, Sobral GR, de Souza R, dos Santos AM, Ferreira MC. Epidemiología a doença meningocócica na cidades do Rio de Janeiro: modificaçes após vacinaçâo contra os sorogrupos B e C. Cad Saúde Públ, Rio de Janeiro. 1997;123(2):295-303.

  20. Galeano A, Echeverry ML. Efectividad de una vacuna antimeningocócica en una cohorte de Itaguí, Colombia. Bol Epidem Antioquia. 1995;20(2).

  21. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa C, Carlone GM, Williams D, Dykes J, Kapeczynski D, Tikhomirov E. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998;177:683-91.

  22. Tappero JW, Lagos R, Ballesteros AM, Plikaytis BD, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, García P, Herrera J, Poolman JT, Perkins BA. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA. 1999;281:1520-7.

  23. Echeverry ML, Malberty JA, Galeano LA, Sotolongo F, Galguera MA, Montoya CM, Martínez O, Nerey MC, Camaraza MA, Bacallao J, Aguirre CA, Alzate LM, Sierra VG, Campa C, Loaiza IB, Montealegre NA, Estrada E, Arroyave M, Restrepo E, Salazar BE. Respuesta inmune humoral a las proteínas de una vacuna antimeningocócica BC en un ensayo realizado en Antioquia, Colombia. Bol Ofic Sanit Panam. 1995;118(4):56-8.

  24. Echeverry ML, Malberty JA, Galeano LA, Sotolongo F, Galguera MA, Montoya CM, Blanco R, Martínez O, Aguirre CA, Alzate LM, Sierra VG, Campa C, Loaiza IB, Montealegre NA, Estrada E, Arroyave M, Restrepo E, Salazar BE. Respuesta inmune humoral al polisacárido capsular de Neisseria meningitidis serogrupo C en un ensayo de vacunación antimeningocócica BC en Antioquia, Colombia. Bol Oficina Sanit Panam. 1995;118(4):73-87.

  25. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to meningococcus, I. The role of natural humoral antibodies. J Exp Med. 1969;129:1078-1307.

  26. Boutriau D, Poolman J, Borrow JR, Findlow J, Diez J, Puig J, Baldó JM, Planelles V, Jubert A, Colomet J, Gil A, Levie K, Kervyn AD, Weynants V, Dominguez F, Barberá R, Sotolongo F. Immunogenicity and safety of three doses of a bivalent meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin and Vacc Immunol. 2007;14(1):65-73.

  27. Ison CA, Anwar N, Cole MJ, Galassini R, Heyderman RS, Klein NJ, West J, Pollard AJ, Morley S, Levin R. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb Pathog. 1999;27 (4):207-14.

  28. Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlates with bactericidal responses. Clin and Diagnostic Lab Immunol. 1998;5(4):479-85.

  29. Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa C, Sierra G, Levin M. Immuno-genicity of a serogroup B meningocococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J. 2001;20:1054-61.

  30. Pérez O, Lastre M, Lapinet J, Bracho G, Díaz M, Zayas C, Taboada C, Sierra G. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine. Infect Immun. 2001;69(7):4502-08.

  31. Pérez O, Lastre M, Lapinet J, Pérez A, Díaz M, Zayas C, Batista A, Quintero Y, Aguiar F, Sánchez R, Sierra G. Long-lasting cellular immune response in babies, children, and preteenagers vaccinated with a proteoliposome based anti-meningococcal BC vaccine. Immunol. 2001;20(4):177-83.

  32. Martínez I, Sierra G, Núñez N, Izquierdo L, Climent Y, Mirabal M. Caracterización de cepas de Neisseria meningitidis aisladas de portadores en Cuba durante 20 años. Rev Cub Med Trop. 2006;58(2):1-17.

  33. Uli L, Castellanos L, Betancourt L, Domínguez F, Barberá R, Sotolongo F et al. Outer membrane vesicles of the VAMENGOC- BC® vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2004;6:3389-99.

  34. Rodríguez T, Pérez O, Ménager N, Ugrinovic S, Bracho G, Mastroeni P. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery. Vaccine. 2005;23:1312- 21.

  35. Pérez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, Zayas C, Acevedo R, González D, López JA, Taboada C, Solís RL. Novel adjuvant based on a proteoliposomederived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biology. 2004;82:603-610.

  36. Pérez O, Bracho G, Lastre M, Zayas C, González D, Gil D, del Campo J, Acevedo R, Taboada C, Rodríguez T, Fajardo ME, Sierra G, Campa C, Mora N, Barberá R, Solís RL. Proteoliposome- derived cochleate as an immunomodulator for nasal vaccine. Vaccine. 2006;24S2:S2/52 -S2/53.

  37. Pérez O, Lastre M. Cabrera O, del Campo J, Bracho G, Cuello M, Balboa J, Acevedo R, Zayas C, Gil D, Mora N, González D, Pérez R, González E, Barberá R, Fajardo EM, Sierra G, Solís RL, Campa C. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol. 2007;66:271-7.




2020     |     www.medigraphic.com